Defendant Name: MiMedx Group, Inc.

Defendant Type: Public Company

Document Reference: court_doc18_19-cv-10927

Document Details

Legal Case Name SEC v. MiMedx Group, Inc., Parker H. Petit, William C. Taylor, Michael J. Senken
Document Name Final Judgment as to Defendant MiMedx Group, Inc.
Document Date 04-Dec-2019
Document Format Civil Proceeding
Case Number 19-cv-10927
Federal District Court New York, Southern District of New York
Federal District Judge Naomi Reice Buchwald
Allegation Type Issuer Reporting and Disclosure
Document Summary On December 4, 2019, the Court issued a final judgment as to Defendant MiMedx Group, Inc. the Court Stated that Defendant "consented to the Court's jurisdiction over Defendant and the subject matter of this action; consented to entry of this Final Judgement without admitting or denying the allegations of the complaint (except as to jurisdiction); waived findings of fact and conclusions of law; and waived any right to appeal from this Final Judgment."

Disgorgement & Penalty Information

Resolutions
Enjoinment
Monetary Penalties:

Civil Penalty

Individual:     $1,500,000.00 Shared:    

Related Documents:

comp24678 26-Nov-2019 Complaint
Complaint and Jury Demand
The SEC stated: "From 2013 through the third quarter of 2017 (the "Relevant Period"), MiMedx, a biotechnology company that specializes in selling wound care and surgical products, engaged in a wide-ranging fraud designed to artificially inflate the company's reported revenue."
LR-24678 26-Nov-2019 Litigation Release
SEC Charges Biotech Company and Executives with Accounting Fraud
The SEC stated that: "[It] charged Georgia-based biotech company MiMedx Group Inc. and three former top executives with defrauding investors by misstating the company's revenue and attempting to cover up their misconduct."
2019-243 26-Nov-2019 Press Release--Civil Action
SEC Charges Biotech Company and Executives With Accounting Fraud
The SEC stated that: "[It] charged Georgia-based biotech company MiMedx Group Inc. and three former top executives with defrauding investors by misstating the company’s revenue and attempting to cover up their misconduct. MiMedx has agreed to a settlement to resolve the claims."

Related Actions:

In the Matter of Paul L. Chancey, Jr., CPA
In the Matter of Michael J. Senken